Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumors (GISTs), though rare, stand as a focal point in cancer research, owing to their unique molecular makeup. These tumors typically arise in the gastrointestinal tract, primarily the stomach or small intestine. Their development is often linked to mutations in genes like KIT or PDGFRA, which play pivotal roles in cell growth regulation. Breakthroughs in targeted therapies, notably with drugs like imatinib, have reshaped GIST treatment by specifically targeting these mutated proteins. Yet, challenges persist, notably in drug resistance. Current investigations delve into innovative treatment avenues and delve into the intricacies of the tumor microenvironment for enhanced diagnostic and therapeutic strategies. By deciphering the intricate biology of GISTs, researchers strive to pave the way for more tailored and effective treatment modalities for this clinically significant yet relatively uncommon cancer.